Search

Your search keyword '"Sdayoor, Inbal"' showing total 10 results
Start Over Author "Sdayoor, Inbal"
10 results on '"Sdayoor, Inbal"'

1. Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma

Author

Fried, Shalev, primary, Shkury, Eden, additional, Itzhaki, Orit, additional, Sdayoor, Inbal, additional, Yerushalmi, Ronit, additional, Shem-Tov, Noga, additional, Danylesko, Ivetta, additional, Jacoby, Elad, additional, Shouval, Roni, additional, Kedmi, Meirav, additional, Marcus, Ronit, additional, Nagler, Arnon, additional, Shimoni, Avichai, additional, and Avigdor, Abraham, additional

Published
2023
Full Text
View/download PDF

2. P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE

Author

Geva, Mika, primary, Fried, Shalev, additional, Itzhaki, Orit, additional, Shem-Tov, Noga, additional, Danylesko, Ivetta, additional, Yerushalmi, Ronit, additional, Marcus, Ronit, additional, Sdayoor, Inbal, additional, Shapira-Frommer, Ronnie, additional, Kedmi, Meirav, additional, Shouval, Roni, additional, Nagler, Arnon, additional, Shimoni, Avichai, additional, and Avigdor, Abraham, additional

Published
2023
Full Text
View/download PDF

3. Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study

Author

Beyar Katz, Ofrat, primary, Perry, Chava, additional, Grisariu‐Greenzaid, Sigal, additional, Yehudai‐Ofir, Dana, additional, Luttwak, Efrat, additional, Avni, Batia, additional, Zuckerman, Tsila, additional, Sdayoor, Inbal, additional, Stepensky, Polina, additional, Ringelstein‐Harlev, Shimrit, additional, Bar‐On, Yael, additional, Libster, Diana, additional, Sharvit, Liat, additional, Amit, Odelia, additional, Greenbaum, Uri, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2023
Full Text
View/download PDF

4. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Author

Beyar-Katz, Ofrat, primary, Perry, Chava, additional, Bar-On, Yael, additional, Grisariu, Sigal, additional, Yehudai-Ofir, Dana, additional, Luttwak, Efrat, additional, Avni, Batia, additional, Zuckerman, Tsila, additional, Sdayoor, Inbal, additional, Stepensky, Polina, additional, Ringelstein-Harlev, Shimrit, additional, Libster, Diana, additional, Sharvit, Liat, additional, Amit, Odelia, additional, Greenbaum, Uri, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

5. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study

Author

Beyar Katz, Ofrat, primary, Perry, Chava, additional, Luttwak, Efrat, additional, Sdayoor, Inbal, additional, Bar-On, Yael, additional, Amit, Odelia, additional, Gold, Ronit, additional, Herishanu, Yair, additional, Benyamini, Noam, additional, Grisariu Greenzaid, Sigal, additional, Avni, Batia, additional, Stepensky, Polina, additional, Libster, Diana, additional, Yehudai-Ofir, Dana, additional, Harlev, Shimrit, additional, Sharvit, Liat, additional, Zuckerman, Tsila, additional, Greenbaum, Uri, additional, Avivi, Irit, additional, and Ram, Ron, additional

Published
2022
Full Text
View/download PDF

6. Early Versus Late CAR-T Therapy in Large B-Cell Lymphoma: Real-World Outcomes

Author

Corona, Magdalena, de Abia, Alejandro Luna, Flynn, Jessica, Sdayoor, Inbal, Fried, Shalev, Devlin, Sean M., Landego, Ivan, Kedmi, Meirav, Shem-Tov, Noga, Shimoni, Avichai, Danylesko, Ivetta, Yerushalmi, Ronit, Marcus, Ronit, Dahi, Parastoo B., Lin, Dr. Richard J., Palomba, M. Lia, Park, Jae H., Salles, Gilles, Nagler, Arnon, Shah, Gunjan L., Avigdor, Abraham, Perales, Miguel-Angel, and Shouval, Roni

Published
2024
Full Text
View/download PDF

9. The Impact of Cardiovascular Vulnerabilities in Non Hodgkin Lymphoma Patients Treated with Chimeric Antigen Receptor T Cell Therapy

Author

Landego, Ivan, Flynn, Jessica R, Goldman, Adam, Devlin, Sean M., Luttwak, Efrat, Luna De Abia, Alejandro, Corona, Magdalena, Kedmi, Meirav, Sdayoor, Inbal, Fried, Shalev, Shem-Tov, Noga, Shimoni, Avichai, Danylesko, Ivetta, Hammoud, Mohammad, Yerushalmi, Ronit, Nagler, Arnon, Marcus, Ronit, El-Moghraby, Ahmed, Rehman, Mahin, Dahi, Parastoo B., Giralt, Sergio A., Lin, Richard J., Palomba, Maria Lia, Scordo, Michael, Shah, Gunjan L., Perales, Miguel-Angel, Mahmood, Syed, Avigdor, Abraham, Liu, Jennifer, and Shouval, Roni

Abstract

INTRODUCTION:CAR-T therapy is an effective treatment for hematological malignancies. However, in recent years there is a growing body of literature suggesting adverse cardiovascular (CV) events among patients treated with CAR-T therapy. Whether cardiovascular risk factors serve as determinants of CV complications and CAR-T outcomes is unclear. The aim of this study is to investigate the landscape and prognostic role of CV comorbidities in patients with non-Hodgkin lymphoma (NHL) treated with autologous CD19- CAR-T.

Published
2023
Full Text
View/download PDF

10. Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma.

Author

Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, and Avigdor A

Abstract

The activity of anti-CD19 CAR T cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and efficacy of CAR T cell therapy in patients with RT (n=30) compared to patients with aggressive B cell lymphoma (n=283) and patients with transformed indolent Non-Hodgkins Lymphoma (iNHL) (n=141) between April 2016 and January 2023. Two-thirds of patients received prior therapy for CLL before RT and 89% of them received B-cell receptor and B-cell lymphoma 2 (BCL-2) inhibitors. Toxicities of CAR T cell therapy in RT were similar to other lymphomas, with no fatalities related to cytokine release syndrome or immune effector-cell associated neurotoxicity synderome. The 100-day overall response rate and complete response rates in patients with RT were 57% and 47%, respectively. With a median follow up of 19 months, the median overall survival (OS) was 9.9 months in patients with RT compared to 18 months in de-novo LBCL and not reached in patients with transformed iNHL. The OS at 12 months was 45% in patients with RT compared with 62% and 75% in patients with de novo LBCL and transformed iNHL, respectively. In a multivariate analysis, worse OS was associated with RT histology, elevated LDH, and more prior lines of therapy. CAR T cell therapy can salvage a proportion of patients with CLL and RT exposed to prior targeted agents; however, efficacy in RT is inferior compared to de novo LBCL and transformed iNHL.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results